New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics
| September 2017 |
Welcome to the September 2017 issue of PharmSource PERISCOPE
This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.
Enjoy the September issue!
CDMOs Buttressed by Resilient Emerging Biopharma Sector
by Saul Richmond, Director of Market Intelligence
Publicly traded emerging biopharmaceutical companies increased their research and development (R&D) expenditure in the second quarter of 2017, reaching almost $3.9 billion, 45% greater than the spending level seen in the second quarter of 2015.
Although the total R&D expenditure of emerging biopharma companies (around $15 billion annually) is a fraction…read on
PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity
| Lead Type | July 2017 | YTD 2017 |
|---|---|---|
| Early Development | 126 | 894 |
| Late Development | 129 | 879 |
| Biologic | 103 | 814 |
| Small Molecule | 300 | 1970 |
| Parenteral | 105 | 857 |
| Oral | 128 | 780 |
| New Financings | 86 | 656 |
| Total Drug Leads | 385 | 2938 |
| Total Device & Diagnostic Leads |
118 | 1105 |
*Total leads include acquisitions/alliances, company acquisition/alliances and events.
Pipeline Tip
Aerie initiates the Phase III Mercury 3 trial with Roclatan for the treatment of glaucoma:
- Therapeutic Area: Ophthalmology
- Dosage Form: Liquid – Sterile
- API: Biologic – Chemical – High potency non-cyto
Get deeper information about the likely upcoming needs of Rebiotix, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
Follow the Money to
Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.
ARMO BioSciences is a US private company that develops immunotherapies for the treatment of cancer, cardiovascular diseases, fibrosis and inflammation. It raised $67 million in a venture capital investment.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund ongoing clinical trials for thier pipeline, including… read on
Follow the Money to
Medical Device & Diagnostic Opportunities
Spotlight on SetPoint Medical Corp.
SSetPoint Medical is a US private company that focuses on implantable neuromodulation devices to treat inflammatory diseases such as Crohn’s disease and rheumatoid arthritis. It raised $30 million in the completion of a venture capital investment.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the clinical development of its Bioelectronic therapy implant for the treatment of chronic… read on
Dose CMOs Stuck in Idle
| PharmSource’s just-released trend report, Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition, reveals several factors for the dose CMO industry’s relatively poor performance in 2016:
1. Rebound in drug development since 2013 is too recent to benefit dose CMOs 2. Heavy investment in captive capacity by global bio/pharma companies 3. Declining significance of dose manufacturing in drug cost of goods as new drugs with high value APIs dominate the pipeline  |
 |
Save the date!
PBOA First Annual Meeting and Conference
October 3rd and 4th at the Bethesda North Marriott in Bethesda, MD
This event is open exclusively to PBOA-member companies!
Get the insider’s view on the regulatory, legislative and market trends driving the biopharmaceutical CDMO industry.
Information on room rates and agenda will be coming soon.
PharmSource Lead Sheet
The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.
Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.
See for yourself how this resource can be a vital tool for building your brand and growing your market share.
To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsource.com / 1-703-383-4903, ext. 112 (ET USA).